about
Impact of co-infections and BCG immunisation on immune responses among household contacts of tuberculosis patients in a Ugandan cohort.Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study.The Use of Interferon Gamma Inducible Protein 10 as a Potential Biomarker in the Diagnosis of Latent Tuberculosis Infection in Uganda.The impact of maternal infection with Mycobacterium tuberculosis on the infant response to bacille Calmette-Guérin immunization.Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus SurvivorsMarburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses.Rethinking Schistosomiasis Vaccine Development: Synthetic Vesicles.Use of QuantiFERON®-TB Gold in-tube culture supernatants for measurement of antibody responses.Ethical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders’ meeting held in Entebbe, UgandaEthical and scientific considerations on the establishment of a controlled human infection model for schistosomiasis in Uganda: report of a stakeholders’ meeting held in Entebbe, UgandaAntibody responses to Schistosoma mansoni schistosomula antigensSchistosoma mansoni schistosomula antigens induce Th1/Pro-inflammatory cytokine responsesRisk assessment for the implementation of controlled human Schistosoma mansoni infection trials in Uganda
P50
Q34456369-8D6A03DF-73BD-4AF2-8C7E-95E798D8B986Q35818084-8747D9B8-684F-4A61-B3FC-50A4EA55C1C2Q35895230-1489573B-E4D4-4537-A7F5-202CACE97D57Q35923817-DD92284E-CEA9-48F9-B501-BC1C7D7022FBQ36947021-06831533-0AA6-442B-B553-B98326536284Q38848150-C0DE8D51-CEDD-4A61-BFF1-45C4B196D379Q38849208-CE808C5D-395A-4003-B9E9-AE9CF95FD6D8Q46172607-6C4B8828-0682-482A-A992-3E9C840A9D3CQ58643312-1B809995-E352-407A-A0CE-20B65609E47AQ58643319-B72A5A52-FCD1-4EF3-A126-7FAC57FCA5F1Q61415126-DC77A031-9A04-41A6-8198-0405AF28788EQ61415127-A4F06BAE-35A0-4A6A-8505-386A7F547B40Q91832683-6BED38B9-64E9-4880-80B6-ECA9A0427D6F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Moses Egesa
@ast
Moses Egesa
@en
Moses Egesa
@es
Moses Egesa
@nl
Moses Egesa
@sl
type
label
Moses Egesa
@ast
Moses Egesa
@en
Moses Egesa
@es
Moses Egesa
@nl
Moses Egesa
@sl
prefLabel
Moses Egesa
@ast
Moses Egesa
@en
Moses Egesa
@es
Moses Egesa
@nl
Moses Egesa
@sl
P106
P21
P31
P496
0000-0001-5136-868X